Hand eczema, or hand dermatitis, is an inflammatory skin condition. Swollen, itchy, scaly, discolored rashes form on the fingers and hands. The skin may blister and crack, and it can be painful. Hand ...

Please provide your email address to receive an email when new articles are posted on . In two phase 3 trials, delgocitinib cream improved hand eczema in a greater proportion of patients vs. vehicle.

NEW YORK, NY — For immediate control of a hand eczema flare, the old soak and smear approach with moisturizers or corticosteroids might live on, but they are moving to the back of the shelf for ...

The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success. Delgocitinib cream significantly improved chronic hand eczema in ...

Treatment options for severe chronic hand eczema are limited and carry troublesome adverse effects. Delgocitinib cream had superior efficacy compared with oral alitretinoin for this patient population ...

A deeper understanding of chronic hand eczema (CHE) -- its pathogenesis, clinical subtypes and presentation, and risk factors -- would help expedite quicker diagnosis and appropriate care. That's the ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI. Chronic hand eczema (CHE) ...

A regulatory decision is expected in the second half of 2025. The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for delgocitinib cream as a treatment for ...

Please provide your email address to receive an email when new articles are posted on . Delgocitinib cream is an investigational, topical pan-Janus kinase inhibitor. Patients treated with delgocitinib ...

Anzupgo (delgocitinib) is the first and only topical medication specifically approved for adults with moderate to severe chronic hand eczema. In large clinical trials, the cream significantly improved ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received FDA clearance for an indication that affects 10% of adults worldwide. The ...

"Chronic Hand Eczema Market"Key players in the Chronic Hand Eczema market include Basilea Pharmaceutica, Stiefel Laboratories, LEO Pharma, Asana Biosciences, and Incyte Corporation, among others.